A randomized, double-blind, placebo controlled, multi-center, Phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) to first-line chemotherapy in patients with optimally debulked (< 1cm) epithelial ovarian cancer
ClinicalTrials.Gov
View All Studies